Drwy ein hymdrechion ar y cyd rydym bellach yn gallu cynnig triniaethau i bobl â salwch difrifol gan gynnwys remdesivir, tocilizumab a sarilumab, sydd mewn llawer o achosion yn golygu nad oes angen gofal critigol arnynt fwyach pan gânt eu derbyn i’r ysbyty. Yn fwy diweddar, rydym wedi gallu rhoi triniaeth gynnar i fwy na 5000 o’r bobl sydd fwyaf agored i niwed yng Nghymru gyda’r meddyginiaethau gwrthfeirol nirmatrelavir/ritonavir, a molnupiravir, a'r gwrthgorff sy’n niwtraleiddio, sotrovimab, er mwyn eu hatal rhag mynd i’r ysbyty o gwbl. Yn ogystal â’n rhaglen frechu, mae galluogi pobl i gael gafael ar driniaethau sy’n seiliedig ar dystiolaeth yn lleihau’r galw ar y GIG ac yn y pen draw yn achub bywydau.
Through our collaborative efforts we are now able to offer people with severe illness treatments including remdesivir, tocilizumab and sarilumab, which in many cases mean they no longer need critical care when they are admitted to hospital. More recently we have been able to provide more than 5000 of the most vulnerable people in Wales early treatment with the antiviral medicines nirmatrelavir/ritonavir, and molnupiravir, and the neutralising antibody sotrovimab, to prevent them being hospitalised at all. In combination with our vaccination programme, enabling people to access evidence-based treatments is reducing demand on our NHS and ultimately saving lives.